Top Febuxostat Brands: Leading Choices for Gout Relief

Febuxostat is a medication commonly prescribed to manage gout by reducing the levels of uric acid in the body. As with many pharmaceuticals, the quality and efficacy of febuxostat can vary between different brands, making it important for patients and healthcare providers to be informed about the most reliable options available. Some brands have garnered a reputation for their consistency and effectiveness, offering patients peace of mind when it comes to managing their condition. In the following article, we will explore some of the top-rated brands of febuxostat that are trusted by medical professionals and patients alike.

Illustration of febuxostat

Best brands of febuxostat in 2025

Uloric

Uloric, developed by Takeda Pharmaceuticals, is a significant brand for febuxostat, approved by the FDA in 2009 as the first new treatment option for hyperuricemia in patients with gout in over 40 years. It is available in 40 mg and 80 mg tablets and has been shown to be effective in reducing serum uric acid levels, with the 80 mg dose achieving this goal in 67% of patients in clinical trials. Despite its efficacy, Uloric has faced recent FDA recommendations limiting its use due to increased cardiovascular risk compared to allopurinol. The medication works by blocking the enzyme xanthine oxidase, preventing uric acid production. Uloric has been studied in multiple clinical trials involving over 4,000 subjects. For more detailed information, visit their official FDA approval release.

Febutaz

Febuxostat, marketed by Sun Pharmaceutical Industries among other brands, is a highly effective xanthine oxidase inhibitor for the chronic management of hyperuricemia in adult patients with gout, particularly those who have an inadequate response or intolerance to allopurinol. Approved by the FDA in 2009, febuxostat reduces serum uric acid levels by 40 to 55% at daily doses of 40-80 mg. Despite a recent recall due to microbial contamination, Sun Pharma's febuxostat remains a significant treatment option, with the drug being distributed nationwide in the U.S. The medication is not recommended for asymptomatic hyperuricemia and carries warnings for cardiovascular events, especially in patients with established cardiovascular disease.

Feburic

Feburic, a brand of febuxostat produced by Menarini, is a highly effective treatment for chronic hyperuricemia in adults with gout, particularly those who have an inadequate response or intolerance to allopurinol. Approved by the European Commission in 2008 and the FDA in 2009, febuxostat works by inhibiting the xanthine oxidase enzyme, reducing serum uric acid levels by 40 to 55% at daily doses of 40-80 mg. The drug is available in film-coated tablets with strengths of 80 mg, and its bioavailability and efficacy have been well-documented in various clinical studies. Febuxostat is approximately 99.2% bound to plasma proteins and has a terminal elimination half-life of 5 to 8 hours. It is a key treatment option for managing gout symptoms and preventing urate crystal deposition. For detailed information regarding febuxostat, refer to the Australian Public Assessment Report for febuxostat.

Adofeb

Dr. Reddy's Laboratories, through its brand Adofeb, is a leading producer of febuxostat tablets, offering a therapeutic equivalent generic version of Uloric approved by the USFDA. Launched in the US market in 2021, Adofeb febuxostat tablets are available in 40 mg and 80 mg strengths, catering to the management of chronic hyperuricemia in adults with gout. The Uloric brand and generic had US sales of approximately $108 million for the twelve months ending in October 2020. Dr. Reddy's febuxostat tablets have been well-received, contributing to the company's 1.3% stock rise upon the announcement. This generic version is crucial for patients who have an inadequate response or intolerance to allopurinol.

Febuxostat-Teva

Febuxostat-Teva, manufactured by Teva Pharmaceuticals, is a leading brand in the febuxostat market, known for its efficacy in treating chronic hyperuricaemia in patients with gout. Teva holds a significant market share, with 35% of the generic medicines segment in Israel and 25% of all prescriptions filled with a Teva product. The drug is available in 80 mg and 120 mg film-coated tablets, with the recommended dose being 80 mg once daily, adjustable to 120 mg if necessary. Febuxostat-Teva has demonstrated superior clinical efficacy and safety in Phase 3 pivotal studies involving over 4100 patients. This brand continues to contribute to the growing febuxostat market, expected to reach USD 2793.75 million by 2031 with a CAGR of 11.4%. For more detailed information about Febuxostat-Teva, refer to the comprehensive datasheet.

Febuxol

Lupin Pharmaceuticals has emerged as a leading producer of febuxostat, with its recent USFDA approval for generic Febuxostat tablets, marking a significant milestone in managing hyperuricemia in adult patients with gout. These tablets, available in 40 mg and 80 mg strengths, are indicated for patients who have an inadequate response to allopurinol or are intolerant to it. The market for febuxostat is expected to grow at a CAGR of 8.61%, reaching USD 1.03 billion by 2024, driven by the increasing prevalence of gout and lifestyle diseases. Lupin's investment of 7.9% of its revenue in research and development in FY23 underscores its commitment to innovation. With estimated annual sales of USD 27 million in the U.S., Lupin's Febuxostat tablets are set to make a significant impact in the market.

Febustat

Febuxostat, produced by Macleods Pharmaceuticals, is a highly effective xanthine oxidase inhibitor used for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response or intolerance to allopurinol. It reduces serum uric acid levels by 40 to 55% at daily doses of 40-80 mg, and its approval by the FDA in 2009 marked a significant milestone in gout treatment. The drug is available in 40 mg and 80 mg tablets and is not recommended for asymptomatic hyperuricemia. Febuxostat's efficacy and safety profile make it a preferred choice, despite potential cardiovascular risks and gout flares during early treatment. Its market is projected to grow significantly, with a CAGR of 8.61% by 2030. For more detailed information on Febuxostat, refer to the official publication.

Febutime

Febuxostat, marketed under brands like Uloric and Adenuric, is a highly effective xanthine oxidase inhibitor produced by several pharmaceutical companies, including Zydus Lifesciences. Zydus, a leading Indian pharmaceutical company, received US FDA approval for their febuxostat tablets, which are used to manage chronic hyperuricemia in adults with gout who have an inadequate response or intolerance to allopurinol. Febuxostat reduces serum uric acid levels by 40 to 55% at daily doses of 40-80 mg, making it a crucial treatment for gout management. The drug has seen significant market growth, with annual sales of USD 32 million in the US as of 2023. Zydus's formulation is manufactured at their facility in Moraiya, Ahmedabad, India. For more detailed information, refer to the Economic Times article.

Febz

Febuxostat, marketed under brands like Uloric and Adenuric, is a highly effective medication for treating chronic gout and hyperuricemia, particularly for patients intolerant to allopurinol. Approved in the European Union in 2008 and the United States in 2009, febuxostat has demonstrated its efficacy in reducing serum uric acid levels by 40 to 55% at daily doses of 40-80 mg. The drug is characterized by its high bioavailability, with at least 84% of the dose absorbed in the gut, and a terminal elimination half-life of approximately 5 to 8 hours. Despite its benefits, febuxostat has been associated with increased cardiovascular risks, leading to specific usage guidelines and warnings. Its stability and consistency have been validated through extensive stability studies, ensuring the product's quality over its shelf life. For more detailed information, you can review the Adenuric public assessment report.

Febustop

Febuxostat, marketed as Febustop by Intas Pharmaceuticals, is a highly effective xanthine oxidase inhibitor used to manage chronic hyperuricemia in adults with gout. It works by reducing serum uric acid levels, with daily doses of 40-80 mg decreasing uric acid concentrations by 40 to 55%. Febustop is particularly beneficial for patients who have an inadequate response or intolerance to allopurinol. The drug is taken once daily, either with or without food, and may be adjusted based on regular blood tests to ensure optimal urate levels. Despite potential side effects like gout flares and liver problems, Febustop remains a crucial treatment option, especially with its long-term efficacy in preventing gout attacks and joint damage.